Prediction in Silico of Pathological Response in a Prospective Cohort Study of Early Breast Cancer Patients

Inclusion Criteria

• •1. Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening biopsy, blood samples and questionnaires
• •2. 18 years old or at time of written consent
• •3. Patient with histologically confirmed breast cancer
• •4. Absence of metastatic disease
• •5. Patient requiring neoadjuvant chemotherapy
• •6. Performance status ≤ 2 (according to WHO criteria)
• •7. Indication of any systemic therapeutic strategy can be performed alongside this current cohort in accordance with national and / or international recommendations.
• •8. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
• •9. Patient must be affiliated to a Social Health Insurance
• •10. For patients taking part in the RTW WP: working patients at time of diagnostic and in sick leave at time of inclusion